Loading...

GRDX GRIDAI TECHNOLOGIES CORP Management Changes 8-K Filing

GRD

GRDX

GRIDAI TECHNOLOGIES CORP

(GRDX)

2025 8-K

Transaction Update

CEO Appointment Update

Management Changes

Director Waiver Notice

Compliance Update

Funding Agreement Signed

Share Exchange Completion

CEO Appointment

Management Change

Stock Split Announcement

Merger of Equals

Delisting due to Non-Compli...

Debt Restructuring

Nasdaq Compliance

Merger Rescission

Management Changes

Nasdaq Compliance Notice

Debt Default Notice

Acquisition Agreement

Nasdaq Compliance Notice

Licensing Agreement

Auditor Resignation

Acquisition and Default on ...

Resignation of Chief Scient...

Warrant Exercise Inducement...

Management Change

Change in Independent Accou...

Merger of Equals

Registered Direct Offering

Amendment to Form 8-K

Earnings Reports

Acquisition of ImmunogenX, ...

Registered Direct Offering

Regulation FD Disclosure

Warrant Exercise Inducement...

Sale of Niclosamide Program

Acquisition of ImmunogenX, ...

Reverse Stock Split

Delisting Notice

Amendment to License Agreement

Warrant Exercise Inducement...

License Agreement with Sanofi

Annual Meeting of Stockholders

Warrant Exercise Inducement...

Retention Bonuses and Annua...

Shareholder Director Nomina...

Private Placement Offering

Nasdaq Compliance

External Links:

Entero Therapeutics Inc reported on March 6, 2025, that it received a notice from Nasdaq about not meeting the minimum bid price requirement for its stock, and it appointed Anna Skowron as CFO and Richard Paolone as CEO, with respective monthly compensations of $8,333 and $12,500.

AI Assistant

GRIDAI TECHNOLOGIES CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.